Introduction and Objective: This study compared accuracy and glycemic control using Dexcom G6 and G7 real-time continuous glucose monitors (rtCGM) integrated into an insulin infusion computer calculator (IICC) workflow for critically ill adult inpatients.Methods: A retrospective analysis evaluated 13 ICU patients using Dexcom G6 and 35 using G7, integrated into an institution-developed IICC workflow using a validation protocol. Accuracy was assessed by comparing matched rtCGM and point-of-care (POC) glucose values using mean absolute relative difference (MARD) and Surveillance Error Grid (SEG) analysis.Results: A total of 1,291 matched glucose pairs were analyzed for G7 and 758 for G6. G7 sensors demonstrated lower MARD (12.5% vs. 15.2%) and a higher percentage of values in SEG Zone A (86% vs. 76%). Both sensors showed high SEG accuracy, with 99.6% (G7) and 99.2% (G6) in the clinically acceptable Zone A+B (Figure). A lower mean glucose (142 vs. 151 mg/dL) and higher time in range (82.8% vs 79.3%) was achieved using G7 compared to G6. The G7 workflow also demonstrated lower time above range >180 mg/dL (14.5% vs. 20.5%). Despite low overall hypoglycemia rates, G7 workflow exhibited slightly higher time below range <70 mg/dL (0.5% vs. 0.18%) and marginally increased time <54 mg/dL (0.1% vs. 0.05%).Conclusion: G7 sensors demonstrated improved accuracy and glycemic performance compared to G6, with the exception of a slight increase in time spent below range.
E.R. Giovannetti: Advisory Panel; Eli Lilly and Company, Sanofi. R.O. Lee: None. R.L. Thomas: Research Support; REMD Therapeutics, Carmot Therapeutics. S.C. Boeder: Consultant; Cecelia Health. Advisory Panel; Novo Nordisk. Consultant; Lexicon Pharmaceuticals, Inc, Persperion Diagnostics. Research Support; Eli Lilly and Company, Carmot Therapeutics, Inc, REMD Therapeutics, Dexcom, Inc., Lexicon Pharmaceuticals, Inc. K. Kulasa: None.
Dexcom provided CGM sensors free of charge for this study.
Source link
Leave a Reply